{"title":"“联合Janus激酶抑制剂和生物制剂治疗顽固性严重特应性皮炎”的勘误表。","authors":"","doi":"10.1111/jdv.20683","DOIUrl":null,"url":null,"abstract":"<p>De Greef A, Baeck M. Combination of Janus kinase inhibitor and biologic for recalcitrant severe atopic dermatitis. J Eur Acad Dermatol 2025;39(1):e94–e97. https://doi.org/10.1111/jdv.20132.</p><p>Regarding Patient #1, who was known to have classical severe atopic dermatitis since childhood, he had, like the other patients in the study, received a combination of a biologic and a JAK inhibitor, with an initial improvement consistent with the results presented in the article. However, he recently experienced yet another treatment failure, and a thorough investigation revealed a cutaneous T-cell lymphoma, likely related to the long-standing progression of his severe atopic dermatitis. Retrospectively, we realize that Figure 1 of the published article likely depicted the early signs of this lymphoma.</p><p>We apologize for this error.</p>","PeriodicalId":17351,"journal":{"name":"Journal of the European Academy of Dermatology and Venereology","volume":"39 6","pages":""},"PeriodicalIF":8.0000,"publicationDate":"2025-04-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/jdv.20683","citationCount":"0","resultStr":"{\"title\":\"Corrigendum to ‘Combination of Janus kinase inhibitor and biologic for recalcitrant severe atopic dermatitis’\",\"authors\":\"\",\"doi\":\"10.1111/jdv.20683\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>De Greef A, Baeck M. Combination of Janus kinase inhibitor and biologic for recalcitrant severe atopic dermatitis. J Eur Acad Dermatol 2025;39(1):e94–e97. https://doi.org/10.1111/jdv.20132.</p><p>Regarding Patient #1, who was known to have classical severe atopic dermatitis since childhood, he had, like the other patients in the study, received a combination of a biologic and a JAK inhibitor, with an initial improvement consistent with the results presented in the article. However, he recently experienced yet another treatment failure, and a thorough investigation revealed a cutaneous T-cell lymphoma, likely related to the long-standing progression of his severe atopic dermatitis. Retrospectively, we realize that Figure 1 of the published article likely depicted the early signs of this lymphoma.</p><p>We apologize for this error.</p>\",\"PeriodicalId\":17351,\"journal\":{\"name\":\"Journal of the European Academy of Dermatology and Venereology\",\"volume\":\"39 6\",\"pages\":\"\"},\"PeriodicalIF\":8.0000,\"publicationDate\":\"2025-04-02\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1111/jdv.20683\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of the European Academy of Dermatology and Venereology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1111/jdv.20683\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"DERMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of the European Academy of Dermatology and Venereology","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/jdv.20683","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"DERMATOLOGY","Score":null,"Total":0}
Corrigendum to ‘Combination of Janus kinase inhibitor and biologic for recalcitrant severe atopic dermatitis’
De Greef A, Baeck M. Combination of Janus kinase inhibitor and biologic for recalcitrant severe atopic dermatitis. J Eur Acad Dermatol 2025;39(1):e94–e97. https://doi.org/10.1111/jdv.20132.
Regarding Patient #1, who was known to have classical severe atopic dermatitis since childhood, he had, like the other patients in the study, received a combination of a biologic and a JAK inhibitor, with an initial improvement consistent with the results presented in the article. However, he recently experienced yet another treatment failure, and a thorough investigation revealed a cutaneous T-cell lymphoma, likely related to the long-standing progression of his severe atopic dermatitis. Retrospectively, we realize that Figure 1 of the published article likely depicted the early signs of this lymphoma.
期刊介绍：
The Journal of the European Academy of Dermatology and Venereology (JEADV) is a publication that focuses on dermatology and venereology. It covers various topics within these fields, including both clinical and basic science subjects. The journal publishes articles in different formats, such as editorials, review articles, practice articles, original papers, short reports, letters to the editor, features, and announcements from the European Academy of Dermatology and Venereology (EADV).
The journal covers a wide range of keywords, including allergy, cancer, clinical medicine, cytokines, dermatology, drug reactions, hair disease, laser therapy, nail disease, oncology, skin cancer, skin disease, therapeutics, tumors, virus infections, and venereology.
The JEADV is indexed and abstracted by various databases and resources, including Abstracts on Hygiene & Communicable Diseases, Academic Search, AgBiotech News & Information, Botanical Pesticides, CAB Abstracts®, Embase, Global Health, InfoTrac, Ingenta Select, MEDLINE/PubMed, Science Citation Index Expanded, and others.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
